IFN-α2b (recombinant human)   Click here for help

GtoPdb Ligand ID: 8338

Synonyms: Intron A® | intronA
Approved drug
IFN-α2b (recombinant human) is an approved drug (FDA (1986))
Compound class: Peptide
Comment: The sequence of IFN-α2b, differs in only one residue from the sequence of the endogenous peptide, with Lys23 being replaced by Arg.
No information available.
Summary of Clinical Use Click here for help
IFN-α2b was used clinically to treat hairy cell leukemia, malignant melanoma, follicular lymphoma, condylomata acuminata (anogenital warts), AIDS-related Kaposi's sarcoma, chronic hepatitis B and chronic hepatitis C. The manufacturer discontinued the medicine for commercial reasons in 2022. A new formulation of the active ingredient is being repurposed by the rare disease startup company Ashlins Pharmaceuticals (announced in July 2026).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
IFN-α2b activates interferon receptors to produce anti-viral, anti-proliferative, anti-tumor and immunomodulatory effects.